What medication is indicated to control hirsutism in Polycystic Ovary Syndrome (PCOS)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 11, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

Spironolactone is the first-line medication for controlling hirsutism in Polycystic Ovary Syndrome (PCOS). The medication works by blocking androgen receptors, addressing the underlying hormonal imbalance in PCOS that causes excessive hair growth 1. The typical starting dose is 50-100 mg daily, which can be gradually increased to 200 mg daily if needed. Treatment should continue for at least 6-12 months before assessing full effectiveness, as hair growth cycles are slow to respond. Some key points to consider when treating hirsutism in PCOS include:

  • Combined oral contraceptives (COCs) containing ethinyl estradiol with anti-androgenic progestins like drospirenone, cyproterone acetate, or dienogest are also effective, either alone or in combination with spironolactone 1.
  • Finasteride (2.5-5 mg daily) and flutamide are second-line options but have more limited evidence.
  • These medications work by blocking androgen receptors or reducing androgen production, addressing the underlying hormonal imbalance in PCOS that causes excessive hair growth.
  • Patients should be counseled that visible results take 3-6 months to appear, and concurrent cosmetic hair removal methods may be used during treatment.
  • For women planning pregnancy, these anti-androgen medications should be discontinued due to potential feminization of male fetuses. It's also important to note that mechanical removal of hair (e.g., plucking, shaving, waxing), electrolysis, and laser vaporization are also used to manage hirsutism, but concomitant medical management directed at reducing androgen levels usually is necessary 1.

From the Research

Medications for Controlling Hirsutism in PCOS

  • The following medications are indicated to control hirsutism in Polycystic Ovary Syndrome (PCOS):
    • Combined oral contraceptives (COCs) such as ethinyl estradiol and cyproterone acetate 2, 3, 4, 5
    • Antiandrogens such as cyproterone acetate, spironolactone, flutamide, and finasteride 4, 5
    • Metformin, an oral antihyperglycemic medication, which has been shown to be potentially effective in reducing hirsutism in women with PCOS 2, 6, 3, 5

Mechanism of Action

  • COCs work by suppressing ovarian androgen secretion and decreasing free testosterone levels 4
  • Antiandrogens work by blocking androgen receptors or inhibiting 5 alpha-reductase activity, which converts testosterone to dihydrotestosterone 4, 5
  • Metformin works by reducing hyperinsulinemia, which is thought to contribute to hirsutism in women with PCOS 2, 6

Efficacy and Safety

  • The efficacy and safety of these medications vary, and the choice of treatment should be individualized based on the severity of hirsutism, presence of other symptoms, and patient preferences 3, 4, 5
  • COCs and antiandrogens are generally effective in reducing hirsutism, but may have side effects such as weight gain, mood changes, and increased risk of thromboembolism 4, 5
  • Metformin is generally well-tolerated, but may have gastrointestinal side effects and requires monitoring of renal function and glucose levels 2, 6

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Metformin or antiandrogen in the treatment of hirsutism in polycystic ovary syndrome.

The Journal of clinical endocrinology and metabolism, 2003

Research

Management of hirsutism.

American journal of clinical dermatology, 2000

Research

The Hirsute woman: challenges in evaluation and management.

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists, 2011

Research

The treatment of polycystic ovary syndrome.

Minerva ginecologica, 2004

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.